EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Dose-intensified PSMA Radioligand Therapy: The Rationale Behind the OPTIMAL-PSMA Trial

Gemma Sheehan-Dare, Sobia Khan, Louise Emmett

European Urology Focus · 2026-10 · 12 (5) · 837-839

DOI: 10.1016/j.euf.2026.07.006 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Urology Focus, 2026-10. Verfasst von Gemma Sheehan-Dare und 2 weiteren Autor:innen. Beteiligte Einrichtung: Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Antigens, Surface, Glutamate Carboxypeptidase II, Radiopharmaceuticals. Die Arbeit nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A key unanswered question in prostate-specific membrane-antigen (PSMA) targeted radioligand therapy is whether we have chosen therapy doses and regimens that are "safe" rather than "effective," with phase 3 trials to date guided by conservative external beam derived dose constraints. However, is increasing administered dose or short interval fractionated dose safe, and does it even make a difference to patient outcomes? The goal of the OPTIMAL-PSMA trial is to determine the depth of response and safety of intense-induction then maintenance dosing compared to standard-of-care six doses 6-weekly [177Lu] Lu-PSMA-597 in men with metastatic castration-resistant prostate cancer (mCRPC). This mini review will evaluate the scientific evidence and rationale for dose intensification with PSMA-targeted radioligand therapy (PSMA-RLT). It will cover existing trials that are evaluating a variety of dose-dense regimens and give a more in-depth overview of the OPTIMAL-PSMA trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantAntigens, SurfaceGlutamate Carboxypeptidase IIRadiopharmaceuticalsLutetiumDipeptidesHumansMaleRadioisotopes

Substanzen

Antigens, SurfaceGlutamate Carboxypeptidase IIFOLH1 protein, humanRadiopharmaceuticalsLutetiumRadioisotopesDipeptidesLutetium-177

Autor:innen und Institutionen

  • Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia.
  • Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, Australia. Electronic address: Louise.emmett@svha.org.au.

Zitieren

APA

Sheehan-Dare, G., Khan, S., & Emmett, L. (2026). Dose-intensified PSMA Radioligand Therapy: The Rationale Behind the OPTIMAL-PSMA Trial. European Urology Focus, 12(5), 837-839. https://doi.org/10.1016/j.euf.2026.07.006

Vancouver

Sheehan-Dare G, Khan S, Emmett L. Dose-intensified PSMA Radioligand Therapy: The Rationale Behind the OPTIMAL-PSMA Trial. European Urology Focus. 2026;12(5):837-839. doi:10.1016/j.euf.2026.07.006

BibTeX
@article{SheehanDare2026,
  author = {Sheehan-Dare, Gemma and Khan, Sobia and Emmett, Louise},
  title = {Dose-intensified PSMA Radioligand Therapy: The Rationale Behind the OPTIMAL-PSMA Trial},
  journal = {European Urology Focus},
  year = {2026},
  volume = {12},
  number = {5},
  pages = {837--839},
  doi = {10.1016/j.euf.2026.07.006}
}
Kostenlos starten →